Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: GlobeNewswire
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid’s leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regulatory approval. The foundation for her expert drug development perspectives began from her early career as a practicing neurologist who treated patients with refractory and treatment-resistant epilepsies and neuromuscular disorders. She has held leadership roles in biopharmaceutical companies and a
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.MarketBeat
- Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics GAAP EPS of -$0.17 misses by $0.02, revenue of $0.13M misses by $0.04M [Seeking Alpha]Seeking Alpha
OVID
Earnings
- 11/12/25 - Miss
OVID
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 11/7/25 - Form DEF
- OVID's page on the SEC website